InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: peregr post# 332158

Friday, 10/25/2019 7:51:53 AM

Friday, October 25, 2019 7:51:53 AM

Post# of 345952
No bother bringing up Fargo details yet.. I am more intrigued by David A Schaer info poached over to Pfizer and Parchoice Therapeutics latest parent surrounding PS Targeting re: CAR EXOSOMES and Michael Kalos exiting of Eli Lilly ..and so many more interesting things than Fargo and sealed court records proving PS Targeting is astronomical

____

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
Clinical Cancer Research

March 1, 2013

Paolo A. Ascierto,
Michael Kalos,
David A. Schaer,
Margaret K. Callahan, and
Jedd D. Wolchok

________

METHOD FOR PREPARING IMMUNE CELL EXOSOME CARRYING CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF

PHARCHOICE THERAPEUTICS INC

Abstract:
(EN) Provided are a method for preparing an immune cell exosome carrying CAR obtained by isolation and an application thereof. After activating a CAR immune cell by a specific antigen, the produced exosome is subjected to further analysis, isolation, purification, and enrichment to finally obtain the immune cell exosome carrying CAR. The exosome can be used to treat a disease such as cancer and a severe infectious disease.
(FR) L'invention concerne un procédé de préparation d'un exosome de cellule immunitaire contenant un CAR obtenu par isolement, ainsi qu'une application associée. Après activation d'une cellule immunitaire CAR par un antigène spécifique, l'exosome produit est soumis à une analyse, à un isolement, à une purification et à un enrichissement supplémentaires en vue d'obtenir finalement l'exosome de cellule immunitaire contenant le CAR. L'exosome peut être utilisé pour traiter une maladie telle qu'un cancer et une maladie infectieuse grave.

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019128952


_____






Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News